Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
CanSinoBIO Signs Deal for Aerosol Delivery of COVID-19 Vaccine
Tianjin CanSinoBIO (SHA: 688185, HK: 06185) partnered with
The aerosolized vaccine is inhaled directly via a cup dispenser into the patient’s airway, a route that is similar to the natural infection pathway of the COVID-19 virus. The companies believe it may have an advantage over other vaccines by generating mucosal immunity.
In addition, the inhaled drug requires a much smaller volume of vaccine than other delivery routes, allowing more patients to access the CanSinoBIO vaccine.
John Power, Aerogen CEO & Founder said “The world has an urgent need for an effective, low cost, globally scalable and globally accessible solution to mass vaccination. The pioneering development undertaken by Aerogen and CanSino has resulted in a system that meets all these requirements and with a capacity to vaccinate in the billions.”
Dr. Xuefeng YU, Chairman and CEO of CanSinoBIO said: “Our partnership with Aerogen started in 2013 and for almost a decade, we’ve been advancing the possibility of aerosol drug delivery. It is demonstrated that the aerosolized vaccine can stimulate mucosal immunity and significantly reduce the risk of transmission, which could be a solution to rapidly build mass immune protection and accelerate the end of the pandemic.”
CanSinoBio is preparing its filing for commercial authorization in
Founded in 2009, CanSinoBIO is dedicated to developing innovative vaccines for
See our other articles on CanSino Bio.
Disclosure: ChinaBio has a relationship with CanSino.